4.5 Article

Structural Basis of Intracellular TGF-β Signaling: Receptors and Smads

期刊

出版社

COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a022111

关键词

-

资金

  1. AbbVie
  2. Bayer Pharma AG
  3. Boehringer Ingelheim
  4. Canada Foundation for Innovation
  5. Eshelman Institute for Innovation
  6. Genome Canada
  7. Innovative Medicines Initiative (EU/EFPIA) (ULTRA-DD) [115766]
  8. Janssen
  9. Merck Co.
  10. Novartis Pharma AG
  11. Ontario Ministry of Economic Development and Innovation
  12. Pfizer
  13. Sao Paulo Research Foundation-FAPESP
  14. Takeda
  15. Wellcome Trust [092809/Z/10/Z]

向作者/读者索取更多资源

Stimulation of the transforming growth factor beta (TGF-beta) family receptors activates an intracellular phosphorylation-dependent signaling cascade that culminates in Smad transcriptional activation and turnover. Structural studies have identified a number of allosteric mechanisms that control the localization, conformation, and oligomeric state of the receptors and Smads. Such mechanisms dictate the ordered binding of substrate and adaptor proteins that determine the directionality of the signaling process. Activation of the pathway has been illustrated by the various structures of the receptor-activated Smads (R-Smads) with SARA, Smad4, andYAP, respectively, whereasmechanisms ofdown-regulationhavebeen elucidated by the structural complexes of FKBP12, Ski, and Smurf1. Interesting parallels have emerged between the R-Smads and the Forkhead-associated (FHA) and interferon regulatory factor (IRF)-associated domains, as well as the Hippo pathway. However, important questions remain as to the mechanism of Smad-independent signaling.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据